Effects of gliclazide dose escalation on postprandial hyperglycemia in type 2 diabetes mellitus: A prospective, open-label, case-controlled, dose-escalation study

Current Therapeutic Research - Clinical and Experimental

Volumn 67, Issue 2, 2006, Pages 81-102

  Naidoo, Poobalan ^a   Virendra, Rambiritch ^a   Layla, Mayet ^b  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b ADDINGTON HOSPITAL   (South Africa)

Author keywords

gliclazide; oral antidiabetic agents; oral hypoglycemic agents; postprandial hyperglycemia; sulfonylureas; type 2 diabetes mellitus

Indexed keywords

ANTIDIABETIC AGENT; FRUCTOSAMINE; GLICLAZIDE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMOGRAPHY; DOSE CALCULATION; DOSE RESPONSE; DRUG TOLERABILITY; FEMALE; FRUCTOSAMINE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEMATOLOGY; HUMAN; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INTERVIEW; KIDNEY FUNCTION TEST; LIVER FUNCTION TEST; MALE; MEAL; MONITORING; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PATIENT COMPLIANCE; PHYSICIAN; POSTPRANDIAL HYPERGLYCEMIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCREENING; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

EID: 33746832419     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.curtheres.2006.04.001     Document Type: Article

References (40)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 329 (1993) 977-986
2. [published correction appears in BMJ. 1999;318:29]. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317 (1998) 703-713
3. Ceriello A. The possible role of postprandial hyperglycaemia in the pathogenesis of diabetic complications. Diabetologia 46 Suppl 1 (2003) M9-M16
4. Avignon A., Radauceanu A., and Monnier L. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care 20 (1997) 1822-1826
5. Bonora E., and Muggeo M. Postprandial blood glucose as a risk factor for cardiovascular disease in Type II diabetes: The epidemiological evidence. Diabetologia 44 (2001) 2107-2114
6. Manderson J., Patterson C., Hadden D., et al. Preprandial versus postprandial blood glucose monitoring in type 1 diabetic pregnancy: A randomized controlled clinical trial. Am J Obstet Gynecol. 189 (2003) 507-512
7. de Veciana M., Major C., Morgan M., et al. Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy. N Engl J Med. 333 (1995) 1237-1241
8. Charbonnel B., Matthews D., Schernthaner G., et al., QUARTET Study Group. A long-term comparison of pioglitazone and gliclazide in patients with type 2 diabetes mellitus: A randomized, double-blind, parallel-group comparison trial. Diabet Med. 22 (2005) 399-405
9. Harrower A. Gliclazide modified release: From once daily administration to 24-hour glucose control. Metabolism 49 Suppl 2 (2000) 7-11
10. Palmer K., and Brogden R. Gliclazide: An update of its pharmacological properties and therapeutic efficacy in non-insulin dependent diabetes mellitus. Drugs 46 (1993) 92-125
11. Melander A. Kinetics-effect relations of insulin-releasing drugs in patients with type 2 diabetes: Brief overview. Diabetes 53 Suppl 3 (2004) S151-S155
12. Shaw K., Wheeley M., Campbell D., and Ward J. Home blood glucose monitoring in non-insulin-dependent diabetics: The effect of gliclazide on blood glucose and weight control, a multicentre trial. Diabet Med. 2 (1985) 484-490
13. [WMA Web site]. World Medical Association (WMA) Declaration of Helsinki. Accessed March 6, 2006. Recommendations Guiding Medical Doctors in Biomedical Research Involving Human Subjects (1989), WMA, Ferney-Voltaire, France Accessed March 6, 2006
14. Available at. South Africa Dept. of Health. The patients' rights charter. Accessed March 7, 2006. http://www.doh.gov.za/docs/legislation/patientsright/chartere.html
15. Expert C.o.t.D.a.C.o.D.M. American Diabetes Association: Clinical practice recommendations 2002. Diabetes Care 25 Suppl 1 (2002) S1-S147
16. Tulloch-Reid M., Williams D., Looker H., et al. Do measures of body fat distribution provide information on the risk of type 2 diabetes in addition to measures of general obesity? Comparison of anthropometric predictors of type 2 diabetes in Pima Indians. Diabetes Care 26 (2003) 2556-2561
17. Buoen C., Holm S., and Thomsen M. Evaluation of the cohort size in phase I dose escalation trials based on laboratory data. J Clin Pharmacol. 43 (2003) 470-476
18. Available at:. World Health Organization (WHO). Obesity: Preventing and Managing the Global Epidemic. Accessed March 7, 2006. WHO Technical Report Series 804 (2000), WHO, Geneva, Switzerland. http://www.whqlibdoc.who.int/trs/WHO_TRS_894.pdf
19. Iverson C., Flanagin A., Fontanrosa P., et al., American Medical Association. American Medical Assocaition Manual of Style: A Guide for Authors and Editors. 9th ed. (1998), Lippincott Williams & Wilkins, Philadelphia, Pa 486-503
20. (Suppl). Guillausseau P. An evaluation of long-term glycemic control in non-insulin-dependent diabetes mellitus: The relevance of glycated hemoglobin. Am J Med. 90 (1991) 46S-49S
21. Kilo C., Dudley J., and Kalb B. Evaluation of the efficacy and safety of Diamicron in non-insulin-dependent diabetic patients. Diabetes Res Clin Pract. 14 Suppl 2 (1991) S79-S82
22. Scott R., and Donnelly T. No effect of gliclazide on gastric inhibitory polypeptide (GIP) in type II diabetes. Diabetes Res Clin Pract. 3 (1987) 175-178
23. Sinay I., Arias P., Schnitman M., et al. Diet only or diet and sulfonylureas in mild type II diabetes (NIDDM)? Pathophysiologic and therapeutic implications. Acta Diabetol Lat. 25 (1988) 289-297
24. Noury J., and Nandeuil A. Comparative three-month study of the efficacies of metformin and gliclazide in the treatment of NIDD. Diabetes Metab. 17 (1991) 209-212
25. Brogard J., Pinget M., and Dorner M. Effect of middle-term gliclazide treatment on insulin secretion in non-insulin dependent diabetics. Curr Med Res Opin. 9 (1984) 56-63
26. Wing J., Panz V., Joffe B., and Seltel H. Changes in glucose disposal and cellular insulin binding in obese black Southern African patients with type 2 diabetes mellitus before and after sulphonylurea therapy. Diabet Med. 10 (1993) 50-55
27. DeFronzo R., Bonadonna R., and Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care 15 (1992) 318-368
28. DeFronzo R., Gunnarsson R., Bjorkman O., et al. Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (type II) diabetes mellitus. J Clin Invest. 76 (1985) 149-155
29. [published correction appears in Lancet. 1999;354:602]. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
30. [published correction appears in Lancet. 1998;352:1558]. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 (1998) 854-865
31. DeFronzo R. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 131 (1999) 281-303
32. [published correction appears in Diabetes Care. 2005; 28:1272]. Ceriello A., Johns D., Widel M., et al. Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes. Diabetes Care 28 (2005) 266-272
33. Rambiritch V. Pharmacokinetics and pharmacodynamics of glibenclamide in type 2 diabetics. dissertation (2004), University of KwaZulu-Natal, KwaZulu-Natal, South Africa
34. Jonsson A., Hallengren B., Rydberg T., and Melander A. Effects and serum levels of glibenclamide and its active metabolites in patients with type 2 diabetes. Diabetes Obes Metab. 3 (2001) 403-409
35. Krentz A., and Bailey C. Oral antidiabetic agents: Current role in type 2 diabetes mellitus. Drugs 65 (2005) 385-411
36. Wahlin-Boll E., Sartor G., Melander A., and Schersten B. Impaired effect of sulfonylurea following increased dosage. Eur J Clin Pharmacol. 22 (1982) 21-25
37. Stenman S., Melander A., Groop P., and Groop L. What is the benefit of increasing the sulfonylurea dose?. Ann Intern Med. 118 (1993) 169-172
38. Jackson L., and Robertson L. Sulphonylureas (specifically glibenclamide) and their correct dosage. S Afr Med J. 76 (1989) 286
39. Heerdink E., Urquhart J., and Leufkens H. Changes in prescribed drug doses after market introduction. Pharmacoepidemiol Drug Saf. 11 (2002) 447-453
40. Rambiritch V., and Naidoo P. Gliclazide modified release. Drugs 65 (2005) 1449-1450